476
|
Aguilar M, Aisa D, Alpat B, Alvino A, Ambrosi G, Andeen K, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Battarbee M, Battiston R, Bazo J, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, Bizzaglia S, Bizzarri M, Boella G, de Boer W, Bollweg K, Bonnivard V, Borgia B, Borsini S, Boschini MJ, Bourquin M, Burger J, Cadoux F, Cai XD, Capell M, Caroff S, Casaus J, Castellini G, Cernuda I, Cerreta D, Cervelli F, Chae MJ, Chang YH, Chen AI, Chen GM, Chen H, Chen HS, Cheng L, Chou HY, Choumilov E, Choutko V, Chung CH, Clark C, Clavero R, Coignet G, Consolandi C, Contin A, Corti C, Gil EC, Coste B, Creus W, Crispoltoni M, Cui Z, Dai YM, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Masso L, Dimiccoli F, Díaz C, von Doetinchem P, Donnini F, Duranti M, D'Urso D, Egorov A, Eline A, Eppling FJ, Eronen T, Fan YY, Farnesini L, Feng J, Fiandrini E, Fiasson A, Finch E, Fisher P, Formato V, Galaktionov Y, Gallucci G, García B, García-López R, Gargiulo C, Gast H, Gebauer I, Gervasi M, Ghelfi A, Giovacchini F, Goglov P, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guandalini C, Guerri I, Guo KH, Haas D, Habiby M, Haino S, Han KC, He ZH, Heil M, Hoffman J, Hsieh TH, Huang ZC, Huh C, Incagli M, Ionica M, Jang WY, Jinchi H, Kanishev K, Kim GN, Kim KS, Kirn T, Korkmaz MA, Kossakowski R, Kounina O, Kounine A, Koutsenko V, Krafczyk MS, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Li HL, Li JQ, Li JQ, Li Q, Li Q, Li TX, Li W, Li Y, Li ZH, Li ZY, Lim S, Lin CH, Lipari P, Lippert T, Liu D, Liu H, Liu H, Lolli M, Lomtadze T, Lu MJ, Lu SQ, Lu YS, Luebelsmeyer K, Luo F, Luo JZ, Lv SS, Majka R, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Morescalchi L, Mott P, Müller M, Nelson T, Ni JQ, Nikonov N, Nozzoli F, Nunes P, Obermeier A, Oliva A, Orcinha M, Palmonari F, Palomares C, Paniccia M, Papi A, Pauluzzi M, Pedreschi E, Pensotti S, Pereira R, Picot-Clemente N, Pilo F, Piluso A, Pizzolotto C, Plyaskin V, Pohl M, Poireau V, Putze A, Quadrani L, Qi XM, Qin X, Qu ZY, Räihä T, Rancoita PG, Rapin D, Ricol JS, Rodríguez I, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Sandweiss J, Saouter P, Schael S, Schmidt SM, von Dratzig AS, Schwering G, Scolieri G, Seo ES, Shan BS, Shan YH, Shi JY, Shi XY, Shi YM, Siedenburg T, Son D, Song JW, Spada F, Spinella F, Sun W, Sun WH, Tacconi M, Tang CP, Tang XW, Tang ZC, Tao L, Tescaro D, Ting SCC, Ting SM, Tomassetti N, Torsti J, Türkoğlu C, Urban T, Vagelli V, Valente E, Vannini C, Valtonen E, Vaurynovich S, Vecchi M, Velasco M, Vialle JP, Vitale V, Vitillo S, Wang LQ, Wang NH, Wang QL, Wang RS, Wang X, Wang ZX, Weng ZL, Whitman K, Wienkenhöver J, Willenbrock M, Wu H, Wu X, Xia X, Xie M, Xie S, Xiong RQ, Xu NS, Xu W, Yan Q, Yang J, Yang M, Yang Y, Ye QH, Yi H, Yu YJ, Yu ZQ, Zeissler S, Zhang C, Zhang JH, Zhang MT, Zhang SD, Zhang SW, Zhang XB, Zhang Z, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Precision Measurement of the Helium Flux in Primary Cosmic Rays of Rigidities 1.9 GV to 3 TV with the Alpha Magnetic Spectrometer on the International Space Station. PHYSICAL REVIEW LETTERS 2015; 115:211101. [PMID: 26636836 DOI: 10.1103/physrevlett.115.211101] [Citation(s) in RCA: 81] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Indexed: 06/05/2023]
Abstract
Knowledge of the precise rigidity dependence of the helium flux is important in understanding the origin, acceleration, and propagation of cosmic rays. A precise measurement of the helium flux in primary cosmic rays with rigidity (momentum/charge) from 1.9 GV to 3 TV based on 50 million events is presented and compared to the proton flux. The detailed variation with rigidity of the helium flux spectral index is presented for the first time. The spectral index progressively hardens at rigidities larger than 100 GV. The rigidity dependence of the helium flux spectral index is similar to that of the proton spectral index though the magnitudes are different. Remarkably, the spectral index of the proton to helium flux ratio increases with rigidity up to 45 GV and then becomes constant; the flux ratio above 45 GV is well described by a single power law.
Collapse
|
477
|
Wang S, Zeng Y, Zhou JM, Nie SL, Peng Q, Gong J, Huo JR. MicroRNA-1246 promotes growth and metastasis of colorectal cancer cells involving CCNG2 reduction. Mol Med Rep 2015; 13:273-80. [PMID: 26573378 DOI: 10.3892/mmr.2015.4557] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Accepted: 09/14/2015] [Indexed: 11/06/2022] Open
Abstract
Colorectal cancer (CRC) is the third most common cancer type and the fourth leading cause of cancer‑associated mortality worldwide. MicroRNA (miR)‑1246 is involved in differentiation, invasion, metastasis and chemoresistance of certain types of tumor cells. CCNG2 encodes an unconventional cyclin homolog, cyclin G2 (CycG2), associated with growth inhibition, which correlated significantly with lymph node metastasis, clinical stage, histological grade and poor overall survival in numerous cancer types. To investigate the regulation of miR‑1246 on CycG2 expression, and their effects on proliferation and metastasis of CRC, HCT‑116 and LOVO cells were transfected with pre‑miR‑1246 anti‑miR‑1246 and their negative controls. It was demonstrated that the expression of miR‑1246 was significantly increased in CRC tissues and cell lines, which was the opposite of CycG2. miR‑1246 negatively regulated the expression of CycG2 in HCT‑116 and LOVO CRC cells. CCNG2 is a direct target of miR‑1246 in CRC cells. Overexpression of miR‑1246 induced cell proliferation, migration and invasion, while knockdown of miR‑1246 inhibited proliferation, migration and invasion in the CRC cells. Upregulation of miR‑1246 mediated the malignant progression of CRC and is partly attributed to the downregulation of the expression of CycG2. Consequently, these findings provided a molecular basis for the role of miR‑1246/CCNG2 in the progression of human CRC and suggested a novel target for the treatment of CRC.
Collapse
|
478
|
Gong J, Chu Y, Xu M, Huo J, Lv L. Esophageal squamous cell carcinoma cell proliferation induced by exposure to low concentration of cigarette smoke extract is mediated via targeting miR-101-3p/COX-2 pathway. Oncol Rep 2015; 35:463-71. [PMID: 26530100 DOI: 10.3892/or.2015.4379] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 09/26/2015] [Indexed: 11/06/2022] Open
Abstract
Cigarette smoke has been implicated as a major risk factor for esophageal squamous cell carcinoma (ESCC). Several lines of evidence have suggested that the promoting effect of cigarette smoking extract (CSE) on ESCC is mediated by upregulation of cyclooxygenase-2 (COX-2) expression. Yet, the underlying molecular and cellular mechanisms of how CSE stimulates COX-2 expression and facilitates ESCC development are largely unknown. In the present study, we revealed microRNA (miR)-101-3p expression was downregulated upon exposure to low concentration of CSE in Eca109 cancer cells, and suppression of miR-101-3p was required for low CSE-induced cell proliferation, presenting as overexpression of miR-101-3p reversing CSE stimulated cancer cell growth. Luciferase assay revealed that COX-2 was a direct target for miR-101-3p and overexpression of miR-101-3p decreased cellular COX-2 protein expression. Furthermore, we found that COX-2 inhibitor and knockdown of COX-2 by siRNA interference could abolish CSE-induced cell proliferation, indicating that promotion of cancer cell proliferation by low concentration of CSE was dependent on COX-2 activity. Finally, downregulation of miR-101-3p expression and upregulation of COX-2 was found in ESCC specimens from patients with smoking history. Taken together, our findings revealed a new post-transcriptional mechanism by which CSE regulated COX-2 expression to favor cancer cell proliferation, suggesting miR-101-3p as a potential biomarker and therapeutic target for smoke-related ESCC.
Collapse
|
479
|
|
480
|
Dai W, Gao J, Gong J, Xia X, Yang H, Shen Y, Gu J, Wang T, Liu Y, Zhou J, Shen Z, Zhu S, Pan Z. Sexual behavior of migrant workers in Shanghai, China. BMC Public Health 2015; 15:1067. [PMID: 26476783 PMCID: PMC4609473 DOI: 10.1186/s12889-015-2385-y] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2015] [Accepted: 10/05/2015] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Rapid urbanization of China has resulted in significant domestic migration. The purpose of the present study was to survey the sexual behavior of migrant workers in Shanghai and determine the risk factors for unprotected sex. METHODS A cross-sectional study of the sexual behavior of 5996 migrant workers was conducted in 7 administrative regions of Shanghai in 2012 from August to October. A self-administered questionnaire was used to collect data. RESULTS Five thousand seven hundred seventy two out of the 5996 migrants enrolled into the present study were primarily young adults aged 34.3 ± 10.6 years. Of them, 73.5 % were married, 51.1 % graduated from junior high school, 46.0 % earned 1500-2500 yuan (RMB) monthly. The majority (82.3 %) of the migrants engaged in sexual behavior, and 58.0 % did not use condoms in sexual intercourse. Some of the participants (15.2 %) had casual extramarital partners within the previous 12 months; among them, 76.2 % never or only occasionally used condoms. The results of the multivariate logistic regression analysis suggested that condom use was associated with age, occupation, monthly income, education, and housing conditions. Having temporary sexual partners was significantly associated with several factors such as unmarried (OR: 0.47, 95 % CI: 0.38-0.57), working at domestic (OR: 1.65,95 % CI: 1.17-2.34), working at wholesale/retail(OR: 1.65, 95 % CI: 1.13-2.13), and male migrants (OR: 2.37, 95 % CI: 1.96-2.85), but not with other factors such as age, monthly income, or education. Having casual extramarital partners was significantly associated with female migrants working at domestic (OR: 1.89, 95 % CI: 1.09-3.28), unmarried male migrants (OR: 0.51, 95 % CI: 0.36-0.74). CONCLUSION Closer attention should be paid to sexual health education among migrant workers, especially women and those working in domestic and wholesale/retail occupations. The use of condoms should be promoted for older (>35 y), low-income, and less-educated individuals.
Collapse
|
481
|
Jia J, Cui Y, Lu M, Wang X, Li J, Li J, Li Y, Zhang X, Gao J, Zhou J, Lu Z, Gong J, Yu J, Sun Z, Liu C, Shen L, Zhang X. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. Clin Transl Oncol 2015; 18:592-8. [PMID: 26459251 DOI: 10.1007/s12094-015-1406-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Accepted: 09/03/2015] [Indexed: 12/14/2022]
Abstract
INTRODUCTION The esophageal squamous cell carcinoma (ESCC) is the predominant pathological type and accounts for more than 80 % of esophageal cancer in China. The successful use of anti-epidermal growth factor receptor (EGFR) treatment in head and neck squamous cell carcinoma provides the rationale for introducing anti-EGFR targeting treatment in ESCC. One of our prospective phase II clinical trials analyzed the efficacy of nimotuzumab, an anti-EGFR agent, combined with chemotherapy (paclitaxel and cisplatin) to treat unresectable ESCC. MATERIALS AND METHODS We analyzed the correlation of the clinical response with EGFR expression by immunohistochemical staining (IHC). RESULTS Totally 55 tumor samples were analyzed. 18/55 (32.7 %) cases were with high EGFR expression while the other 37/55 (67.3 %) cases were with low to moderate EGFR expression. The expression of EGFR was not related to gender, age, tumor location, tumor differentiation and clinical stage of disease. The objective response rate (ORR) in high EGFR expression group was 55.6 % (10/18) while that in low to moderate EGFR expression group was 54.1 % (20/37) (P = 0.57). Both the progression-free survival (PFS) and overall survival (OS) in high EGFR expression group were much shorter than those in low to moderate EGFR expression group (PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5 ± 1.5 months, P = 0.03). CONCLUSIONS The results showed that over-expression of EGFR was related to poor survival of ESCC. The over-expression of EGFR by IHC might not be an ideal predictive biomarker of nimotuzumab treatment. Other EGFR pathway-associated molecules should be analyzed in further studies.
Collapse
|
482
|
Freimark B, Gong J, Ye D, Nguyen V, Yin S, Archer R, Hughes C, Hutchins J, Hutchins J, Schroit A, Brekken R, Huang X. Abstract A46: Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 and B16 mouse melanoma. Cancer Immunol Res 2015. [DOI: 10.1158/2326-6074.tumimm14-a46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The underlying cause for the failure of immune checkpoint blockade is the overwhelming, persistent and multifocal immune suppression in the tumor microenvironment. This is due to the absence of pre-existing antitumor Teff because of the action of important upstream immune checkpoints that recruit tumor infiltrating myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs) and M2 macrophages, which also produce potent immunosuppressive cytokines (e.g., TGF-beta and IL-10). Phosphatidylserine (PS) is an upstream immune checkpoint that drives global immunosuppression. Previous work has shown that PS targeting agents can override PS-driven immunosuppression and re-program the tumor microenvironment from immunosuppressive to immunosupportive, break tumor immune tolerance, and elicit potent de novo antitumor T-cell immunity.
Methods: In the present study, the antitumor effect of the combination of a PS-targeting antibody with antibodies that inhibit the immune checkpoints programmed death receptor-1 (PD-1) or cytotoxic T-lymphocyte associated antigen (CTLA-4) in the K1735 mouse melanoma model was examined. Tumor-bearing mice were treated with each antibody alone or the combination at 5 to 10 mg/kg, twice a week. Tumor growth, survival, as well as intra-tumoral and peripheral immune cell profiles after treatment were assessed by FACS and IHC.
Results: Here we demonstrate that combination of PS-targeting antibody (mch1N11) with anti-PD-1 or anti-CTLA-4 antibodies significantly improved therapeutic efficacy in mice bearing K1735 melanoma compared to single agent treatment. Similar results were seen in the B16 mouse melanoma model. Importantly, we found that the level of MDSCs in the spleen was significantly reduced by combination treatment, 9.9% in the combination treated group, as compared with 18.27% and 14.69% in anti-PD-1 (p<0.0005) or control C44 (p<0.05) treated group, respectively. In addition, combination therapy had the highest ratio of tumor-infiltrating immune effector to suppressor cells and the most IL-2 and IFNγ-secreting T cells in the spleen in response to non-specific stimulation. The percentage of IFNγ-secreting CD8+ T cells in the combination group was 5.85%, as compared with 4.1% and 4.0% in anti-PD-1 or control C44 group, respectively (p<0.05). The percentage of IL-2-secreting CD8+ T cells in the combination group was 2.4%, as compared with 1.29% and 1.17% in anti-PD-1 or control C44 group, respectively (p<0.05). The percentage of IL-2-secreting CD4+ T cells in the combination group was 6.5%, as compared with 2.9% and 3.2% in anti-PD-1 or control C44 group, respectively (p<0.05). Finally, combination of PS-targeting with downstream immune checkpoint blockade did not induce any observable toxicity following multiple treatment doses.
Conclusions: Our findings indicate that the combination of PS-blockade with blockade of downstream immune checkpoints (e.g., PD-1 and CTLA-4) represents a promising strategy to enhance the efficacy of cancer immunotherapy.
Citation Format: Bruce Freimark, Jian Gong, Dan Ye, Van Nguyen, Shen Yin, Rich Archer, Chris Hughes, Jeff Hutchins, Jeff Hutchins, Alan Schroit, Rolf Brekken, Xianming Huang. Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 and B16 mouse melanoma. [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2015;3(10 Suppl):Abstract nr A46.
Collapse
|
483
|
Zeng LL, Long L, Shen H, Fang P, Song Y, Zhang L, Xu L, Gong J, Zhang Y, Zhang Y, Xiao B, Hu D. Gray Matter Loss and Related Functional Connectivity Alterations in A Chinese Family With Benign Adult Familial Myoclonic Epilepsy. Medicine (Baltimore) 2015; 94:e1767. [PMID: 26496303 PMCID: PMC4620778 DOI: 10.1097/md.0000000000001767] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Benign adult familial myoclonic epilepsy (BAFME) is a non-progressive monogenic epilepsy syndrome. So far, the structural and functional brain reorganizations in BAFME remain uncharacterized. This study aims to investigate gray matter atrophy and related functional connectivity alterations in patients with BAFME using magnetic resonance imaging (MRI).Eleven BAFME patients from a Chinese pedigree and 15 matched healthy controls were enrolled in the study. Optimized voxel-based morphometric and resting-state functional MRI approaches were performed to measure gray matter atrophy and related functional connectivity, respectively. The Trail-Making Test-part A and part B, Digit Symbol Test (DST), and Verbal Fluency Test (VFT) were carried out to evaluate attention and executive functions.The BAFME patients exhibited significant gray matter loss in the right hippocampus, right temporal pole, left orbitofrontal cortex, and left dorsolateral prefrontal cortex. With these regions selected as seeds, the voxel-wise functional connectivity analysis revealed that the right hippocampus showed significantly enhanced connectivity with the right inferior parietal lobule, bilateral middle cingulate cortex, left precuneus, and left precentral gyrus. Moreover, the BAFME patients showed significant lower scores in DST and VFT tests compared with the healthy controls. The gray matter densities of the right hippocampus, right temporal pole, and left orbitofrontal cortex were significantly positively correlated with the DST scores. In addition, the gray matter density of the right temporal pole was significantly positively correlated with the VFT scores, and the gray matter density of the right hippocampus was significantly negatively correlated with the duration of illness in the patients.The current study demonstrates gray matter loss and related functional connectivity alterations in the BAFME patients, perhaps underlying deficits in attention and executive functions in the BAFME.
Collapse
|
484
|
Zhang C, Doherty JA, Burgess S, Hung RJ, Lindström S, Kraft P, Gong J, Amos CI, Sellers TA, Monteiro ANA, Chenevix-Trench G, Bickeböller H, Risch A, Brennan P, Mckay JD, Houlston RS, Landi MT, Timofeeva MN, Wang Y, Heinrich J, Kote-Jarai Z, Eeles RA, Muir K, Wiklund F, Grönberg H, Berndt SI, Chanock SJ, Schumacher F, Haiman CA, Henderson BE, Amin Al Olama A, Andrulis IL, Hopper JL, Chang-Claude J, John EM, Malone KE, Gammon MD, Ursin G, Whittemore AS, Hunter DJ, Gruber SB, Knight JA, Hou L, Le Marchand L, Newcomb PA, Hudson TJ, Chan AT, Li L, Woods MO, Ahsan H, Pierce BL. Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Hum Mol Genet 2015; 24:5356-66. [PMID: 26138067 PMCID: PMC4550826 DOI: 10.1093/hmg/ddv252] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 06/03/2015] [Accepted: 06/25/2015] [Indexed: 11/29/2022] Open
Abstract
Epidemiological studies have reported inconsistent associations between telomere length (TL) and risk for various cancers. These inconsistencies are likely attributable, in part, to biases that arise due to post-diagnostic and post-treatment TL measurement. To avoid such biases, we used a Mendelian randomization approach and estimated associations between nine TL-associated SNPs and risk for five common cancer types (breast, lung, colorectal, ovarian and prostate cancer, including subtypes) using data on 51 725 cases and 62 035 controls. We then used an inverse-variance weighted average of the SNP-specific associations to estimate the association between a genetic score representing long TL and cancer risk. The long TL genetic score was significantly associated with increased risk of lung adenocarcinoma (P = 6.3 × 10(-15)), even after exclusion of a SNP residing in a known lung cancer susceptibility region (TERT-CLPTM1L) P = 6.6 × 10(-6)). Under Mendelian randomization assumptions, the association estimate [odds ratio (OR) = 2.78] is interpreted as the OR for lung adenocarcinoma corresponding to a 1000 bp increase in TL. The weighted TL SNP score was not associated with other cancer types or subtypes. Our finding that genetic determinants of long TL increase lung adenocarcinoma risk avoids issues with reverse causality and residual confounding that arise in observational studies of TL and disease risk. Under Mendelian randomization assumptions, our finding suggests that longer TL increases lung adenocarcinoma risk. However, caution regarding this causal interpretation is warranted in light of the potential issue of pleiotropy, and a more general interpretation is that SNPs influencing telomere biology are also implicated in lung adenocarcinoma risk.
Collapse
|
485
|
Qiu H, Huang F, Gong J, Xiao H, Sun BL, Yang RG. TRIM22 can activate the noncanonical NF-κB pathway by affecting IKKα. J Recept Signal Transduct Res 2015; 35:289-94. [PMID: 25510414 DOI: 10.3109/10799893.2014.977450] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Tripartite motif 22 (TRIM22) is involved in various cellular processes. It has been reported that TRIM22 can activate nuclear factor-κB (NF-κB) pathway, but the precise mechanism remains unclear. In this study, we explored the exact role of TRIM22 in activating the NF-κB pathway. Different to tumor necrosis factor-α (TNF-α) induction, we found that the overexpression of TRIM22 could induce the processing of p100 to p52 in HEK293T cells. Furthermore, based on the results of co-immunoprecipitation and co-localization experiments, we demonstrated that TRIM22 could interact with IκB kinase (IKK)α but not IKKβ and could increase the level and phosphorylation of IKKα through its really interesting new gene (RING) and spla-ryanodine receptor (SPRY) domains. These results suggest that TRIM22 is able to activate the noncanonical but not the canonical NF-κB pathway by activating IKKα. This finding will aid our understanding of the biological function of TRIM22.
Collapse
|
486
|
Kong W, Chen Z, Zhang W, Gong J, Ke J, Xu H. [Correlation of bone mineral density of the mandibular angle, hand and total body in 839 healthy individuals aged from 5 to 18 years]. ZHONGHUA KOU QIANG YI XUE ZA ZHI = ZHONGHUA KOUQIANG YIXUE ZAZHI = CHINESE JOURNAL OF STOMATOLOGY 2015; 50:540-543. [PMID: 26759296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVES To investigate the correlation of bone mineral density (BMD) of mandibular angle, hand and total body in healthy individuals aged from 5 to 18 years. METHODS Eight hundred and thirty-nine healthy individuals from 5 to 18 years old (422 males, 417 females) in 5 primary and secondary schools in Guangzhou were divided into 14 age groups. Dual energy X-ray absorptiometry (DXA) was used to measure the BMD of mandibular angle, hand and total body. The data were statistically analyzed using Pearson correlation analysis. RESULTS The BMD of mandibular angle increased with age. In females, the BMD of mandibular angle increased quickly from 12 to 16 years old, and its increasing rate gradually slowed down after 16 years old. In males, the BMD of mandibular angle increased quickly after 14 years old, and its increase had not been stopped until 18 years old. Females in 12, 13, 14, 15, 16, 17-year-old group had significantly higher mandibular angle BMD [(0.95 ± 0.19), (1.01 ± 0.17), (1.11 ± 0.17), (1.25 ± 0.13), (1.28 ± 0.14), (1.30 ± 0.13) g/cm(2)] than males in the age-matched group (P < 0.05). There was no significant difference between mandibular angle BMD in males and in females at the age of 18, and from 5 to 11 years old (P > 0.05). For males, the mandibular angle BMD was highly correlated with age (r = 0.696, P < 0.001), hand BMD (r = 0.779, P < 0.001) and total body BMD (r = 0.831, P < 0.001). For females, the mandibular angle BMD was highly correlated with age (r = 0.795, P < 0.001), hand BMD (r = 0.839, P < 0.001) and total body BMD (r = 0.872, P < 0.001). CONCLUSIONS The mandibular angle BMD in healthy individuals from 5 to 18 years old increased with age. The mandibular angle BMD was closely related to hand BMD and total body BMD.
Collapse
|
487
|
Guo B, Xu Y, Gong J, Tang Y, Shang J, Xu H. Reference data and percentile curves of body composition measured with dual energy X-ray absorptiometry in healthy Chinese children and adolescents. J Bone Miner Metab 2015; 33:530-9. [PMID: 25319556 DOI: 10.1007/s00774-014-0615-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Accepted: 06/26/2014] [Indexed: 11/28/2022]
Abstract
Measurements of body composition by dual-energy X-ray absorptiometry (DXA) have evident value in evaluating skeletal and muscular status in growing children and adolescents. This study aimed to generate age-related trends for body composition in Chinese children and adolescents, and to establish gender-specific reference percentile curves for the assessment of muscle-bone status. A total of 1541 Chinese children and adolescents aged from 5 to 19 years were recruited from southern China. Bone mineral content (BMC), lean mass (LM) and fat mass (FM) were measured for total body and total body less head (TBLH). After 14 years, total body LM was significantly higher in boys than girls (p < 0.001). However, total body FM was significantly higher in girls than boys in age groups 13-19 years (p < 0.01). Both LM and FM were consistent independent predictors of total body and subcranial bone mass in both sexes, even after adjustment for the well-known predictors of BMC. The results of multiple linear regression identified LM as the stronger predictor of total body and subcranial skeleton BMC while the fat mass contributed less. For all the subjects, significant positive correlations were observed between total body LM, height, total body BMC and subcranial BMC (p < 0.01). Subcranial BMC had a better correlation with LM than total body BMC. We have also presented gender-specific percentile curves for LM-for-height and BMC-for-LM which could be used to evaluate and follow various pediatric disorders with skeletal manifestations in this population.
Collapse
|
488
|
Freimark B, Gong J, Ye D, Brekken R, Yin S, Hutchins J, Nguyen V, Hughes C, Huang X. Abstract 252: Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Phosphatidylserine (PS) is a phospholipid normally residing in the inner leaflet of the plasma membrane and becomes exposed abundantly on tumor endothelial cells, tumor-secreted microvesicles, and tumor cells in response to chemo- and radiotherapy. Extensive studies have shown that PS is a global immune checkpoint and major contributor to tumor immunosuppression, which promotes the expansion of immunosuppressive cells, such MDSC and M2 macrophages, inhibits DCs maturation, while stimulates them to secrete immunosuppressive mediators. We have shown that PS targeting can override PS-mediated immunosuppression, reactivate innate tumor immunity, and evoke adaptive antitumor immunity. In the present study, we assessed the antitumor effect of the combination of PS blockade and anti-CTLA-4 or anti-PD-1 antibodies in B16 and K1735 melanoma models. Both combinations showed significantly superior tumor growth inhibition over single treatment, with many mice achieving complete tumor regression. Flow cytometry analysis showed that the combination treatment had significantly greater total and functional tumor-infiltrating CD8+ T, more IL-2- and IFNγ-producing splenic T cells, and lower number of splenic MDSCs than did single treatment. In addition, the ratio of M2 to M1 in the tumor was significantly lower in the combination treatment than that in single treatment. Finally, no toxicity was observed in any of the treatment groups following multiple treatment doses. These data suggest that combination of PS blockade with immune checkpoint blockade promotes strong, localized, enhanced therapeutic efficacy without the side-effects of systemic immune activation and represents a promising combinatorial strategy for cancer immunotherapy. A chimeric PS-targeting antibody, bavituximab, is being used in combination with chemotherapy to treat patients with solid tumors in multiple late-stage clinical trials. These data support our Phase I IST evaluation of our PS-targeting antibody bavituximab in combination with ipilimumab in advanced melanoma patients.
Citation Format: Bruce Freimark, Jian Gong, Dan Ye, Rolf Brekken, Shen Yin, Jeff Hutchins, Van Nguyen, Chris Hughes, Xianming Huang. Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 252. doi:10.1158/1538-7445.AM2015-252
Collapse
|
489
|
Gong J, Yin S, Nguyen V, Hutchins J, Freimark BD. Abstract 4289: Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-4289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Phosphatidylserine (PS) is a phospholipid normally residing in the inner leaflet of the plasma membrane that becomes exposed on tumor vascular endothelial cells (ECs) and tumor cells. PS exposure becomes enhanced in response to chemotherapy, irradiation, and oxidative stresses in the tumor microenvironment. PS exposure in tumors promotes an immunosuppressive microenvironment which includes the recruitment of myeloid derived suppressor cells (MDSCs), immature dendritic cells and M2-like macrophages, as well as, the production of anti-inflammatory cytokines. Binding of PS targeting antibodies on tumor endothelial cells, tumor cells and their secreted microparticles triggers an Fc-FcR mediated pro-inflammatory cellular and cytokine response that reverses the immunosuppressive PS meditated checkpoint, thereby enhancing anti-tumor immunity. A chimeric PS-targeting antibody, bavituximab, is being used in combination with chemotherapy to treat patients with solid tumors in multiple late-stage clinical trials. Using breast tumors in immune competent mice, we demonstrate PS targeting antibodies enhance the anti-tumor activity of combination therapies including anti-PD-1 antibodies. Tumor growth inhibition correlates with statistically significant increases in the infiltration of CD8+ T cells and a reduction of myeloid-derived suppressor cells (MDSCs). The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation.
Citation Format: Jian Gong, Shen Yin, Van Nguyen, Jeff Hutchins, Bruce D. Freimark. Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4289. doi:10.1158/1538-7445.AM2015-4289
Collapse
|
490
|
Thrift AP, Gong J, Peters U, Chang-Claude J, Rudolph A, Slattery ML, Chan AT, Locke AE, Kahali B, Justice AE, Pers TH, Gallinger S, Hayes RB, Baron JA, Caan BJ, Ogino S, Berndt SI, Chanock SJ, Casey G, Haile RW, Du M, Harrison TA, Thornquist M, Duggan DJ, Le Marchand L, Lindor NM, Seminara D, Song M, Wu K, Thibodeau SN, Cotterchio M, Win AK, Jenkins MA, Hopper JL, Ulrich CM, Potter JD, Newcomb PA, Hoffmeister M, Brenner H, White E, Hsu L, Campbell PT. Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev 2015; 24:1024-31. [PMID: 25976416 PMCID: PMC4490960 DOI: 10.1158/1055-9965.epi-14-1309] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2014] [Accepted: 05/01/2015] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND High body mass index (BMI) is consistently linked to increased risk of colorectal cancer for men, whereas the association is less clear for women. As risk estimates from observational studies may be biased and/or confounded, we conducted a Mendelian randomization study to estimate the causal association between BMI and colorectal cancer. METHODS We used data from 10,226 colorectal cancer cases and 10,286 controls of European ancestry. The Mendelian randomization analysis used a weighted genetic risk score, derived from 77 genome-wide association study-identified variants associated with higher BMI, as an instrumental variable (IV). We compared the IV odds ratio (IV-OR) with the OR obtained using a conventional covariate-adjusted analysis. RESULTS Individuals carrying greater numbers of BMI-increasing alleles had higher colorectal cancer risk [per weighted allele OR, 1.31; 95% confidence interval (CI), 1.10-1.57]. Our IV estimation results support the hypothesis that genetically influenced BMI is directly associated with risk for colorectal cancer (IV-OR per 5 kg/m(2), 1.50; 95% CI, 1.13-2.01). In the sex-specific IV analyses higher BMI was associated with higher risk of colorectal cancer among women (IV-OR per 5 kg/m(2), 1.82; 95% CI, 1.26-2.61). For men, genetically influenced BMI was not associated with colorectal cancer (IV-OR per 5 kg/m(2), 1.18; 95% CI, 0.73-1.92). CONCLUSIONS High BMI was associated with increased colorectal cancer risk for women. Whether abdominal obesity, rather than overall obesity, is a more important risk factor for men requires further investigation. IMPACT Overall, conventional epidemiologic and Mendelian randomization studies suggest a strong association between obesity and the risk of colorectal cancer.
Collapse
|
491
|
Song M, Gong J, Giovannucci EL, Berndt SI, Brenner H, Chang-Claude J, Curtis KR, Harrison TA, Hoffmeister M, Hsu L, Jiao S, Le Marchand L, Potter JD, Schoen RE, Seminara D, Slattery ML, White E, Wu K, Ogino S, Fuchs CS, Hunter DJ, Tworoger SS, Hu FB, Rimm E, Jensen M, Peters U, Chan AT. Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer 2015; 137:154-64. [PMID: 25431318 PMCID: PMC4405454 DOI: 10.1002/ijc.29360] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2014] [Accepted: 11/05/2014] [Indexed: 01/18/2023]
Abstract
Circulating adiponectin has been associated with lower risk of colorectal cancer (CRC). Genome-wide association studies have identified several single-nucleotide polymorphisms (SNPs) associated with adiponectin levels. However, it is unclear whether these SNPs are associated with CRC risk. In addition, previous data on SNPs in the adiponectin pathway and their associations with CRC are inconsistent. Therefore, we examined 19 SNPs in genes related to adiponectin or its receptors and their associations with CRC using logistic regression among 7,020 cases and 7,631 controls drawn from ten studies included in the Genetics and Epidemiology of Colorectal Cancer Consortium. Using data from a subset of two large cohort studies, we also assessed the contribution of individual SNPs and an adiponectin genetic score to plasma adiponectin after accounting for lifestyle factors among 2,217 women and 619 men. We did not find any statistically significant association between the 19 adiponectin-associated SNPs and CRC risk (multivariable-adjusted odds ratios ranged from 0.89 to 1.05, all p > 0.05). Each SNP explained less than 2.50% of the variance of plasma adiponectin, and the genetic score collectively accounted for 2.95 and 1.42% of the variability of adiponectin in women and men, respectively, after adjustment for age, body mass index, physical activity, smoking, alcohol consumption, regular use of aspirin or nonsteroidal anti-inflammatory drug and postmenopausal hormone use. In conclusion, our findings do not support an association between known adiponectin-related common SNPs and CRC incidence. However, known common SNPs account for only a limited proportion of the interindividual variance in circulating adiponectin. Further work is warranted to investigate the relationship between adiponectin and CRC while accounting for other components in the pathway.
Collapse
|
492
|
Irwin JS, Gong J, Pavord D. SU-E-T-19: A Comparison of the Dosimetric Effects of Brass Mesh and Superflab Boluses. Med Phys 2015. [DOI: 10.1118/1.4924380] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
493
|
Khalili H, Gong J, Brenner H, Austin TR, Hutter CM, Baba Y, Baron JA, Berndt SI, Bézieau S, Caan B, Campbell PT, Chang-Claude J, Chanock SJ, Chen C, Hsu L, Jiao S, Conti DV, Duggan D, Fuchs CS, Gala M, Gallinger S, Haile RW, Harrison TA, Hayes R, Hazra A, Henderson B, Haiman C, Hoffmeister M, Hopper JL, Jenkins MA, Kolonel LN, Küry S, LaCroix A, Marchand LL, Lemire M, Lindor NM, Ma J, Manson JE, Morikawa T, Nan H, Ng K, Newcomb PA, Nishihara R, Potter JD, Qu C, Schoen RE, Schumacher FR, Seminara D, Taverna D, Thibodeau S, Wactawski-Wende J, White E, Wu K, Zanke BW, Casey G, Hudson TJ, Kraft P, Peters U, Slattery ML, Ogino S, Chan AT. Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis 2015; 36:999-1007. [PMID: 26071399 DOI: 10.1093/carcin/bgv086] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2015] [Accepted: 06/06/2015] [Indexed: 12/12/2022] Open
Abstract
Although genome-wide association studies (GWAS) have separately identified many genetic susceptibility loci for ulcerative colitis (UC), Crohn's disease (CD) and colorectal cancer (CRC), there has been no large-scale examination for pleiotropy, or shared genetic susceptibility, for these conditions. We used logistic regression modeling to examine the associations of 181 UC and CD susceptibility variants previously identified by GWAS with risk of CRC using data from the Genetics and Epidemiology of Colorectal Cancer Consortium and the Colon Cancer Family Registry. We also examined associations of significant variants with clinical and molecular characteristics in a subset of the studies. Among 11794 CRC cases and 14190 controls, rs11676348, the susceptibility single nucleotide polymorphism (SNP) for UC, was significantly associated with reduced risk of CRC (P = 7E-05). The multivariate-adjusted odds ratio of CRC with each copy of the T allele was 0.93 (95% CI 0.89-0.96). The association of the SNP with risk of CRC differed according to mucinous histological features (P heterogeneity = 0.008). In addition, the (T) allele was associated with lower risk of tumors with Crohn's-like reaction but not tumors without such immune infiltrate (P heterogeneity = 0.02) and microsatellite instability-high (MSI-high) but not microsatellite stable or MSI-low tumors (P heterogeneity = 0.03). The minor allele (T) in SNP rs11676348, located downstream from CXCR2 that has been implicated in CRC progression, is associated with a lower risk of CRC, particularly tumors with a mucinous component, Crohn's-like reaction and MSI-high. Our findings offer the promise of risk stratification of inflammatory bowel disease patients for complications such as CRC.
Collapse
|
494
|
Hsu L, Jeon J, Brenner H, Gruber SB, Schoen RE, Berndt SI, Chan AT, Chang-Claude J, Du M, Gong J, Harrison TA, Hayes RB, Hoffmeister M, Hutter CM, Lin Y, Nishihara R, Ogino S, Prentice RL, Schumacher FR, Seminara D, Slattery ML, Thomas DC, Thornquist M, Newcomb PA, Potter JD, Zheng Y, White E, Peters U. A model to determine colorectal cancer risk using common genetic susceptibility loci. Gastroenterology 2015; 148:1330-9.e14. [PMID: 25683114 PMCID: PMC4446193 DOI: 10.1053/j.gastro.2015.02.010] [Citation(s) in RCA: 114] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Revised: 02/05/2015] [Accepted: 02/10/2015] [Indexed: 02/06/2023]
Abstract
BACKGROUND & AIMS Risk for colorectal cancer (CRC) can be greatly reduced through screening. To aid in the development of screening strategies, we refined models designed to determine risk of CRC by incorporating information from common genetic susceptibility loci. METHODS By using data collected from more than 12,000 participants in 6 studies performed from 1990 through 2011 in the United States and Germany, we developed risk determination models based on sex, age, family history, genetic risk score (number of risk alleles carried at 27 validated common CRC susceptibility loci), and history of endoscopic examinations. The model was validated using data collected from approximately 1800 participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, conducted from 1993 through 2001 in the United States. RESULTS We identified a CRC genetic risk score that independently predicted which patients in the training set would develop CRC. Compared with determination of risk based only on family history, adding the genetic risk score increased the discriminatory accuracy from 0.51 to 0.59 (P = .0028) for men and from 0.52 to 0.56 (P = .14) for women. We calculated age- and sex-specific 10-year CRC absolute risk estimates based on the number of risk alleles, family history, and history of endoscopic examinations. A model that included a genetic risk score better determined the recommended starting age for screening in subjects with and without family histories of CRC. The starting age for high-risk men (family history of CRC and genetic risk score, 90%) was 42 years, and for low-risk men (no family history of CRC and genetic risk score, 10%) was 52 years. For men with no family history and a high genetic risk score (90%), the starting age would be 47 years; this is an intermediate value that is 5 years earlier than it would be for men with a genetic risk score of 10%. Similar trends were observed in women. CONCLUSIONS By incorporating information on CRC risk alleles, we created a model to determine the risk for CRC more accurately. This model might be used to develop screening and prevention strategies.
Collapse
|
495
|
Thrift AP, Gong J, Peters U, Chang-Claude J, Rudolph A, Slattery ML, Chan AT, Esko T, Wood AR, Yang J, Vedantam S, Gustafsson S, Pers TH, Baron JA, Bezieau S, Küry S, Ogino S, Berndt SI, Casey G, Haile RW, Du M, Harrison TA, Thornquist M, Duggan DJ, Le Marchand L, Lemire M, Lindor NM, Seminara D, Song M, Thibodeau SN, Cotterchio M, Win AK, Jenkins MA, Hopper JL, Ulrich CM, Potter JD, Newcomb PA, Schoen RE, Hoffmeister M, Brenner H, White E, Hsu L, Campbell PT. Mendelian randomization study of height and risk of colorectal cancer. Int J Epidemiol 2015; 44:662-72. [PMID: 25997436 DOI: 10.1093/ije/dyv082] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/23/2015] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND For men and women, taller height is associated with increased risk of all cancers combined. For colorectal cancer (CRC), it is unclear whether the differential association of height by sex is real or is due to confounding or bias inherent in observational studies. We performed a Mendelian randomization study to examine the association between height and CRC risk. METHODS To minimize confounding and bias, we derived a weighted genetic risk score predicting height (using 696 genetic variants associated with height) in 10,226 CRC cases and 10,286 controls. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for associations between height, genetically predicted height and CRC. RESULTS Using conventional methods, increased height (per 10-cm increment) was associated with increased CRC risk (OR = 1.08, 95% CI = 1.02-1.15). In sex-specific analyses, height was associated with CRC risk for women (OR = 1.15, 95% CI = 1.05-1.26), but not men (OR = 0.98, 95% CI = 0.92-1.05). Consistent with these results, carrying greater numbers of (weighted) height-increasing alleles (per 1-unit increase) was associated with higher CRC risk for women and men combined (OR = 1.07, 95% CI = 1.01-1.14) and for women (OR = 1.09, 95% CI = .01-1.19). There was weaker evidence of an association for men (OR = 1.05, 95% CI = 0.96-1.15). CONCLUSION We provide evidence for a causal association between height and CRC for women. The CRC-height association for men remains unclear and warrants further investigation in other large studies.
Collapse
|
496
|
Huang X, Gong J, Nguyen V, Yin S, Baldwin C, Brekken RA, King S, Hutchins J, Freimark B. Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.3059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
497
|
Freimark B, Gong J, Nguyen V, Yin S, Archer R, Hutchins J. Abstract P5-04-12: Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p5-04-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Phosphatidylserine (PS) is a phospholipid normally residing in the inner leaflet of the plasma membrane and becomes exposed on tumor vascular endothelial cells (ECs) and tumor cells. PS exposure becomes enhanced in response to chemotherapy, irradiation, and oxidative stresses in the tumor microenvironment. PS exposure in tumors promotes an immunosuppressive microenvironment which includes the recruitment of myeloid derived suppressor cells (MDSCs), immature dendritic cells, and M2-like macrophages as well as the production of anti-inflammatory cytokines. Binding of PS targeting antibodies on tumor endothelial cells, tumor cells and their secreted microparticles triggers an Fc-FcR mediated pro-inflammatory cellular and cytokine response that reverses the immunosuppressive PS meditated checkpoint, thereby enhancing anti-tumor immunity. A chimeric PS-targeting antibody, bavituximab, is being used in combination with chemotherapy to treat patients with solid tumors in multiple late-stage clinical trials. Using breast tumors in immune competent mice, we demonstrate PS targeting antibodies enhance the anti-tumor activity of anti-CTLA-4 and anti-PD-1 antibodies in the presence and absence of conventional chemotharapy. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation.
Citation Format: Bruce Freimark, Jian Gong, Van Nguyen, Shen Yin, Rich Archer, Jeff Hutchins. Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-04-12.
Collapse
|
498
|
Aguilar M, Aisa D, Alpat B, Alvino A, Ambrosi G, Andeen K, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Battarbee M, Battiston R, Bazo J, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bigongiari G, Bindi V, Bizzaglia S, Bizzarri M, Boella G, de Boer W, Bollweg K, Bonnivard V, Borgia B, Borsini S, Boschini MJ, Bourquin M, Burger J, Cadoux F, Cai XD, Capell M, Caroff S, Casaus J, Cascioli V, Castellini G, Cernuda I, Cerreta D, Cervelli F, Chae MJ, Chang YH, Chen AI, Chen H, Cheng GM, Chen HS, Cheng L, Chou HY, Choumilov E, Choutko V, Chung CH, Clark C, Clavero R, Coignet G, Consolandi C, Contin A, Corti C, Cortina Gil E, Coste B, Creus W, Crispoltoni M, Cui Z, Dai YM, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Masso L, Dimiccoli F, Díaz C, von Doetinchem P, Donnini F, Du WJ, Duranti M, D'Urso D, Eline A, Eppling FJ, Eronen T, Fan YY, Farnesini L, Feng J, Fiandrini E, Fiasson A, Finch E, Fisher P, Galaktionov Y, Gallucci G, García B, García-López R, Gargiulo C, Gast H, Gebauer I, Gervasi M, Ghelfi A, Gillard W, Giovacchini F, Goglov P, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guandalini C, Guerri I, Guo KH, Haas D, Habiby M, Haino S, Han KC, He ZH, Heil M, Hoffman J, Hsieh TH, Huang ZC, Huh C, Incagli M, Ionica M, Jang WY, Jinchi H, Kanishev K, Kim GN, Kim KS, Kirn T, Kossakowski R, Kounina O, Kounine A, Koutsenko V, Krafczyk MS, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Levi G, Li HL, Li JQ, Li Q, Li Q, Li TX, Li W, Li Y, Li ZH, Li ZY, Lim S, Lin CH, Lipari P, Lippert T, Liu D, Liu H, Lolli M, Lomtadze T, Lu MJ, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Lv SS, Majka R, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Morescalchi L, Mott P, Müller M, Ni JQ, Nikonov N, Nozzoli F, Nunes P, Obermeier A, Oliva A, Orcinha M, Palmonari F, Palomares C, Paniccia M, Papi A, Pauluzzi M, Pedreschi E, Pensotti S, Pereira R, Picot-Clemente N, Pilo F, Piluso A, Pizzolotto C, Plyaskin V, Pohl M, Poireau V, Postaci E, Putze A, Quadrani L, Qi XM, Qin X, Qu ZY, Räihä T, Rancoita PG, Rapin D, Ricol JS, Rodríguez I, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Sandweiss J, Saouter P, Sbarra C, Schael S, Schmidt SM, Schulz von Dratzig A, Schwering G, Scolieri G, Seo ES, Shan BS, Shan YH, Shi JY, Shi XY, Shi YM, Siedenburg T, Son D, Spada F, Spinella F, Sun W, Sun WH, Tacconi M, Tang CP, Tang XW, Tang ZC, Tao L, Tescaro D, Ting SCC, Ting SM, Tomassetti N, Torsti J, Türkoğlu C, Urban T, Vagelli V, Valente E, Vannini C, Valtonen E, Vaurynovich S, Vecchi M, Velasco M, Vialle JP, Vitale V, Vitillo S, Wang LQ, Wang NH, Wang QL, Wang RS, Wang X, Wang ZX, Weng ZL, Whitman K, Wienkenhöver J, Wu H, Wu X, Xia X, Xie M, Xie S, Xiong RQ, Xin GM, Xu NS, Xu W, Yan Q, Yang J, Yang M, Ye QH, Yi H, Yu YJ, Yu ZQ, Zeissler S, Zhang JH, Zhang MT, Zhang XB, Zhang Z, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P, Zurbach C. Precision Measurement of the Proton Flux in Primary Cosmic Rays from Rigidity 1 GV to 1.8 TV with the Alpha Magnetic Spectrometer on the International Space Station. PHYSICAL REVIEW LETTERS 2015; 114:171103. [PMID: 25978222 DOI: 10.1103/physrevlett.114.171103] [Citation(s) in RCA: 129] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Indexed: 06/04/2023]
Abstract
A precise measurement of the proton flux in primary cosmic rays with rigidity (momentum/charge) from 1 GV to 1.8 TV is presented based on 300 million events. Knowledge of the rigidity dependence of the proton flux is important in understanding the origin, acceleration, and propagation of cosmic rays. We present the detailed variation with rigidity of the flux spectral index for the first time. The spectral index progressively hardens at high rigidities.
Collapse
|
499
|
Zhang H, Gong J, Zhang H, Kong D. Induction of apoptosis and reversal of permeability glycoprotein-mediated multidrug resistance of MCF-7/ADM by ginsenoside Rh2. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2015; 8:4444-4456. [PMID: 26191135 PMCID: PMC4503007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 04/26/2015] [Indexed: 06/04/2023]
Abstract
Multidrug resistance is a phenomenon that cancer cells develop a cross-resistant phenotype against several unrelated drugs, and permeability glycoprotein derived from the overexpression of multidrug resistance gene 1 has been taken as the most significant cause of multidrug resistance. In the present study, ginsenoside Rh2 was used to reverse permeability glycoprotein-mediated multidrug resistance of MCF-7/ADM cell line. Effects of ginsenoside Rh2 on the apoptotic process and caspase-3 activity of MCF-7 and MCF-7/ADM cell lines were determined using flow cytometry and microplate reader. Methyl thiazolyl tetrazolium test was conducted to assess the IC50 values of ginsenoside Rh2 and adriamycin on MCF-7 and MCF-7/ADM cultures; Rhodamin 123 assay was used to assess the retention of permeability glycoprotein after ginsenoside Rh2 treatment; flow cytometry and real time polymerase chain reaction were used to determine the expression levels of permeability glycoprotein and multidrug resistance gene 1 in drug-resistant cells and their parental cells after exposure to ginsenoside Rh2. The results showed that ginsenoside Rh2, except for inducing apoptosis, had the ability to reverse multidrug resistance in MCF-7/ADM cell line without changing the expression levels of permeability glycoprotein and multidrug resistance gene 1. Our findings provided some valuable information for the application of ginsenoside Rh2 in cancer therapy, especially for multidrug resistance reversal in clinic.
Collapse
|
500
|
Zhou J, Gong J, Ding C, Chen G. Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145. Mol Med Rep 2015; 12:3127-31. [PMID: 25937243 DOI: 10.3892/mmr.2015.3679] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Accepted: 01/30/2015] [Indexed: 11/05/2022] Open
Abstract
Ovarian cancer is one of the most malignant types of cancer of the female human reproductive track, posing a severe threat to the health of the female population. Numerous previous studies have demonstrated that microRNA (miR)-145 is downregulated in ovarian cancer, and that quercetin can inhibit the growth of cancer cells via regulating the expression of miRs. Therefore, the present study investigated the effect of quercetin on the expression of miR-145 in SKOV-3 and A2780 human ovarian cancer cell lines. The results revealed that the expression levels of cleaved caspase-3 in the SKOV-3 and A2780 cells were significantly increased following treatment to induce overexpression of miR-145 compared with treatment with quercetin alone (P<0.01). However, the expression of cleaved caspase-3 in the anti-miR-145 (miR-145 inhibitor) group of cells was markedly decreased compared with that in the miR-145 overexpression group (P<0.01). Taken together, the results suggested that treatment with quercetin induced the apoptosis of human ovarian carcinoma cells through activation of the extrinsic death receptor mediated and intrinsic mitochondrial apoptotic pathways.
Collapse
|